Excited to share a new review from Endevica Bio examining melanocortin drug development to understand why a clinically validated target kept failing.
Key insight: past failures reflected limitations of the molecules tested—not the melanocortin system itself.
www.frontiersin.org/journals/end...
1 month ago
0
0
0
0